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Abstract
We examined the association between serum alpha-fetoprotein (AFP) level and sustained virological response (SVR) in 93
chronic hepatitis C patients. The SVR rate was much higher among patients with serum AFP levels below rather than above
the median value (5.7 ng/ml) (58.7% and 19.2%, respectively; P,0.0001). Serum AFP should be added to the list of factors
predictive of treatment response in chronic hepatitis C.
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Introduction
Serum alpha-fetoprotein (AFP) is a fetal glycoprotein produced
by the yolk sac and fetal liver [1]. Following birth, AFP levels
decrease rapidly to less than 20 ng/ml and increase significantly in
certain pathologic conditions. Serum AFP is a debated, but
routinely used marker for hepatocellular carcinoma (HCC) in
patients with chronic liver disease [2]. Yet, significant elevations of
AFP are commonly seen in non-hepatic malignancies and benign
conditions, such as acute and chronic viral hepatitis [3].
In a previous study [4], we have demonstrated that AFP was
negatively associated with treatment response in 100 patients with
chronic hepatitis C in Egypt. Indeed, the sustained virological
response (SVR) rate was 40.8% among patients with AFP above
the median value (4.5 ng/mL), and 80.4% for patients with AFP
below the median value (P,0.001). Adjustment for other factors
associated with SVR (age, gender, body mass index, steatosis
score, fibrosis stage, ALT level, hemoglobin level, clotting time,
HCV RNA viral load, and treatment dose received) did not affect
the relationship. One limitation of the study was that patients were
almost all (99%) infected with HCV genotype 4, and hence results
may not be applicable to other genotypes. In this paper, we
present the results of a similar study performed in France among
patients infected with other HCV genotypes.
Methods
Participants
This retrospective study included patients with chronic hepatitis
C who attended the Liver Unit at Necker Hospital, Paris, during
2002, and in whom antiviral therapy was initiated during this
period. The inclusion criteria for antiviral therapy were: age over
18 years, positive serology for HCV antibodies, positive HCV
RNA, and a pathological METAVIR score strictly higher than
A1F1. Exclusion criteria were classic contraindications to
interferon or ribavirin therapy, including autoimmune disorders,
pregnancy, limiting psychiatric, ophthalmological or cardiological
disorders, platelet count less than 75,000/mm
3, neutrophil counts
less than 1500 cells/mm
3, and haemoglobin levels less than 10 g/
dl. Child-Pugh C cirrhosis, and positive hepatitis B antigen were
also excluded. Antiviral therapy included pegylated interferon
alpha-2b (PEG intron, Schering Plough) and ribavirin (Rebetol,
Schering Plough), initially given as a function of the patient’s
weight. The initial dosage was always higher than 1 mg/kg/week
subcutaneously for pegylated interferon alpha-2b and 10.6 mg/
kg/day orally for ribavirin. The duration of treatment was defined
according to consensus recommendations according to genotype,
HCV viral load, presence of cirrhosis and failure of previous
treatment. All patients were followed for at least 6 months after
treatment discontinuation in order to assess their SVR. HCV
RNA was measured in the serum using the reverse PCR
(COBAS
TM Amplicator
TM, Roche). Genotyping was performed
using the Inno-Lipa assay (Innogenetics, Ghent, Belgium). Hepatic
necroinflammation and fibrosis were assessed by the METAVIR
scoring system [5]. Fibrosis was staged on a scale of F0–F4:
F0=no fibrosis, F1=portal tract expansion by fibrosis, F2=less
than 50% bridging fibrosis, F3=more than 50% bridging fibrosis
without cirrhosis, and F4=established cirrhosis. Steatosis was
staged as follows: 0: no steatosis, 1: 1–29% of hepatocytes, 2: 30–
49% of hepatocytes and 3: $50% of hepatocytes.
Ethics
This study is based on the retrospective analysis (performed in
2007) of clinical and laboratory data collected in 2002 as part of
the routine management of patients with chronic hepatitis C in the
Liver Unit at Necker Hospital, Paris, France. A specific study code
number was created for each patient so that no name or identifier
other than age and sex appears in the database. Neither informed
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2391Table 1. Relationship between socio-demographical, biological and histological variables and SVR among 93 chronic hepatitis C
patients treated with combined therapy.
Variable n (%) Number of SVR (%) Univariate OR (95% CI) p Multivariate
1 OR (95% CI) p
Gender
Female 39 (41,9) 20 (51,3) 1,00
Male 54 (58,1) 16 (29,6) 0,40 (0,17–0,94) 0,036
Age (year)
#42 25 (26,9) 14 (56,0) 1,00
42–48 22 (23,7) 6 (27,3) 0,29 ( 0,09–1,00)
48–56 22 (23,7) 9 (40,9) 0,54 (0,17–1,73) 0,161
.56 24 (25,8) 7 (29,2) 0,32 (0,10–1,05)
BMI (kg/m2)
#25 43 (51,2) 18 (41,9) 1,00
.25 41 (48,8) 15 (36,6) 0,80 (0,33–1,93) 0,621
Creatinin (micromol/L)
#83 47 (52,8) 17 (36,2) 1,00
.83 42 (47,2) 16 (38,1) 1,08 (0,46–2,57) 0,851
Hemoglobin (g/dL)
#14,4 48 (52,2) 27 (56,3) 1,00
.14,4 44 (47,8) 9 (20,5) 0,20 (0,08–0,51) 0,001
AST (IU/L)
,25 (female) or
30 (male)
12 (12,9) 6 (50,0) 1,00
$25 or 30 81 (87,1) 30 (37,0) 0,59 (0,17–1,99) 0,390
ALT (IU/L)
,25 (female) or
30 (male)
7 (7,5) 4 (57,1) 1,00
$25 or 30 86 (92,5) 32 (37,2) 0,44 (0,09–2,11) 0,298
GGT (IU/L)
,=72 46 (49,5) 29 (63,0) 1,00 1,00
.72 47 (50,5) 7 (14,9) 0,10 (0,04–0,28) 0,0001 0,14 (0,04–0,56) 0,005
Alkalin Phosphatase (IU/L)
,=84 48 (51,6) 21 (43,8) 1,00
.84 45 (48,4) 15 (33,3) 0,64 (0,28–1,49) 0,304
Platelets (x103/mm3)
$150 54 (60,0) 27 (50,0) 1,00
,150 36 (40,0) 8 (22,2) 0,29 (0,11–0,74) 0,008
Total Bilirubin (mg/dL)
#10 40 (51,3) 16 (40,0) 1,00
.10 38 (48,7) 14 (36,8) 0,88 (0,35–2,18) 0,775
Viral load (6103 IU/ml)
#475 43 (50,6) 17 (39,5) 1,00
.475 42 (49,4) 15 (35,7) 0,85 (0,35–2,04) 0,716
AFP (ng/mL)
#2,8 23 (24,7) 16 (69,6) 1,00 1,00
2,8–5,7 23 (24,7) 11 (47,8) 0,40 (0,12–1,34) 0,66 (0,16–2,77)
5,7–9,9 23 (24,7) 4 (17,4) 0,09 (0,02–0,37) 0,001 0,51 (0,09–2,80) 0,854
.9,9 24 (25,8) 5 (20,8) 0,11 (0,03–0,43) 0,84 (0,13–5,44)
Steatosis score
0 11 (14,5) 7 (63,6) 1,00
1 39 (51,3) 11 (28,2) 0,22 (0,05–0,92)
2 17 (22,4) 5 (29,4) 0,24 (0,05–1,19)
3 9 (11,8) 1 (11,1) 0,07 (0,01–0,80) 0,065
Alpha-Fetoprotein and HCV
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2391consent nor ethics approval was asked for this analysis, since it is
exclusively retrospective and did not require any additional testing
other than that performed as part of routine management of
patients in 2002.
Statistical methods
The initial database contained 104 individuals. Those who were
infected with genotype 4 (n=4), and those with HIV co-infection
(n=7), were excluded from the analysis so that the assessment of
AFP predictive value would be carried out only in HIV-negative
non genotype 4-infected individuals. Most continuous variables
were categorised according to medians or quartiles, except for
body mass index (# or .25 kg/m2), platelets (, or $150,000/
mm3), AST (, or $25 and 30 UI/L for females and males,
respectively) and ALT (, or $25 and 30 UI/L for females and
males, respectively). Factors associated with SVR were examined
in univariate and multivariate logistic regression. Factors retained
in the final multivariate regression model all had P values less than
0.05, except for AFP which was forced into the model. Likelihood
ratio tests were used to determine P values.
All analyses were performed using Stata 9.0 statistical software
(Stata Corporation, College Station, TX, USA).
Results
Baseline clinical, biological, virological and histological charac-
teristics of the participants are given in Table 1. The majority
(58.1%) of patients were males, with median age of 48 years.
Seventy-three (78.5%) had significant ($F2) fibrosis, and 52
(55.9%) had severe ($F3) fibrosis. Infecting HCV genotypes were
1 (62.4%), 2 (7.5%), 3 (27.9%), 5 (1.1%) and 6 (1.1%). Median
(IQR) serum AFP level was 5.7 (2.8–9.9) ng/ml, with values
ranging from 1.2 to 103 ng/ml.
The SVR rate was 36/93 (38.7%), and decreased with increasing
levels of serum AFP: 69.6%, 47.8%, 17.4%, and 20.8%, for the 1st,
2nd, 3rd, and 4th quartiles, respectively (P=0.001). Also, the SVR
rate was 58.7% and 19.2% for those with serum AFP under and
above the median value, respectively (OR=0.17, 95% CI=0.06–
0.42; P,0.0001). For patients infected with genotype 1, SVR rates
for patients with fibrosis scores of 0–2 (low to moderate) and 3–4
(severe) were 54.5% and 13.9%, respectively. For patients infected
with other genotypes (2,3,5, and 6), the SVR rates for the same
fibrosis categories were 84.2% and 18.8%, respectively.
Other factors associated with SVR in univariate analysis were
gender, haemoglobin level, serum AST, serum gamma-glutamyl
transpeptidase (GGT), and platelet counts (Table 1). In multivar-
iate analysis, only serum GGT above the median level, severe
fibrosis, and genotype 1 infection were negatively and indepen-
dently associated with SVR. AFP was no longer significant in
multivariate analysis, after introduction of the variables ‘‘severe
fibrosis’’ and ‘‘serum GGT’’ in the model. Of note, serum AFP
and GGT were strongly correlated (spearman rank coeffi-
cient=0.61, P,0.0001), and median AFP levels were significantly
higher among patients with severe fibrosis compared to others
(12.6 versus 4.8 ng/ml, respectively, P=0.002). There was no
interaction between genotypes and serum AFP, i.e., the OR of the
association between serum AFP and SVR was no different for
patients infected with HCV genotype 1 and others.
Discussion
This study confirms our previous findings regarding the predictive
role of AFP with regard to treatment response inchronic hepatitis C.
In this study, the odds of treatment failure was six times higher for
those with serum AFP above the median value (5.7 ng/ml), a figure
identical to that observed in our previous study among Egyptian
patients infected with HCV genotype 4 (OR=5.9; median value
4.5 ng/ml) [4]. This effect is far from negligible, and of the same
magnitude than that of other well-accepted predictive factors of
treatment response such as HCV genotype. Of interest, patients in
this study were infected with various genotypes, the majority being
genotype 1, thus confirming that our initial observation was not
genotype 4-specific. Based on these results, clinicians should take
serum AFP results into account in their evaluation of patient’s
likelihood of responding to treatment.
The multivariate analysis provides us with additional informa-
tion on the mechanisms by which serum AFP might be associated
with treatment response. One difference with our previous study is
the disappearance of the association between AFP and SVR in
multivariate analysis, after controlling for both serum GGT and
liver fibrosis. These two factors have been shown associated with
lower treatment response rates elsewhere [6,7]. In our previous
Variable n (%) Number of SVR (%) Univariate OR (95% CI) p Multivariate
1 OR (95% CI) p
missing 16
Adequate
2 dose of treatment
No 42 (46,2) 16 (38,1) 1,00
Yes 49 (53,8) 18 (36,7) 0,94 (0,40–2,21) 0,894
Fibrosis score (METAVIR)
#2 41 (44,1) 28 (68,3) 1,00 1,00
.2 52 (55,9) 8 (15,4) 0,08 (0,03–0,23) 0,0001 0,18 (0,05–0,60) 0,005
Genotype
Genotype
2,3,5,6
35 (37,6) 19 (54,3) 1,00 1,00
Genotype 1 58 (62,4) 17 (29,3) 0,35 (0,14–0,84) 0,018 0,26 (0,08–0,87) 0,029
1Multivariate analysis includes GGT, AFP, Fibrosis score and genotype
OR, odds-ratio; CI, confidence interval, AFP, alpha-foetoprotein; GGT, serum gamma glutamyl transpeptidase
2Dose of treatment was considered adequate if patients had received at least 80% of the intended dose for at least 80% of the duration of treatment
doi:10.1371/journal.pone.0002391.t001
Table 1. cont.
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dently associated with SVR after controlling for known factors
associated with SVR, including liver fibrosis. In that study, it was
the association between liver fibrosis and SVR which was
completely removed after introducing serum AFP level into the
model. Thus, there seems to be important correlations among liver
fibrosis, serum AFP, and serum GGT, one acting as a confounder
of the other in the association with SVR depending on the study
population. Hepatic progenitor cells (HPC) may be the unifying
factor explaining these observations. HPC arise in the periportal
region of the liver and may be responsible for liver regeneration.
They express high levels of AFP, certain keratin markers, and
GGT [8–10]. Their presence is related to the severity of fibrosis
[11], and their activation has been documented in parallel with
cells associated with the development of fibrosis (stellate cells) [12].
Hence, the joint association observed in this study among AFP,
GGT, liver fibrosis and SVR may be the reflection of more intense
HPC expression in non responders compared to responders. Quite
interestingly, HPC expression has recently been associated with
response to treatment, being higher in non-responders and
relapsers compared with responders [11].
In conclusion, this study confirms the value of serum AFP levels
in predicting treatment outcome in patients with chronic hepatitis
C, regardless of the infecting genotype. Higher levels of serum
AFP may correspond to higher expression of HPC in individuals
developing liver fibrosis.
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